(Q44927006)

7 December 2017

title

Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate (English)

1 reference

7 December 2017

main subject

fluticasone propionate

1 reference

Tom C Fardon

1

1 reference

7 December 2017

Daniel K C Lee

2

1 reference

7 December 2017

Kay Haggart

3

1 reference

7 December 2017

Lesley C McFarlane

4

1 reference

7 December 2017

Brian J Lipworth

5

1 reference

7 December 2017

language of work or name

English

0 references

publication date

7 June 2004

1 reference

American Journal of Respiratory and Critical Care Medicine

7 December 2017

published in

1 reference

7 December 2017

volume

170

1 reference

7 December 2017

issue

9

1 reference

7 December 2017

page(s)

960-966

1 reference

Inhaled glucocorticoids for asthma

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

Efficacy and safety of inhaled corticosteroids. New developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

A comparison of the efficacy and safety of inhaled corticosteroids in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

Long-term effects of budesonide or nedocromil in children with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

Use of inhaled corticosteroids and risk of fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

An in vitro comparison of commonly used topical glucocorticoid preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

Adrenal suppression with inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

Measuring the systemic effects of inhaled beclomethasone: timed morning urine collections compared with 24 hour specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

Pharmacokinetics and pharmacodynamics of inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

Bioavailability and metabolism of mometasone furoate: pharmacology versus methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

21 January 2018

Mometason furoate levels

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

Dynamic Modeling of Cortisol Reduction after Inhaled Administration of Fluticasone Propionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-500OC

10.1164/RCCM.200404-500OC

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference